MC
MCK.US McKesson Corporation
- Market cap
- USD 127B
- P/E
- 28.4x
- P/B
- 5.04x
- ROE
- -
- Dividend yield
- 0.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MCK.US undervalued?
Graham numberMCK.US trades 152.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
McKesson Corporation fundamental analysis
No fundamental analysis for McKesson Corporation yet.
McKesson Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinic…
Full company profileMcKesson Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
McKesson Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 199B | 208B | 214B | 231B | 238B | 264B | 277B | 309B | 359B | 403B | 433B |
| Gross Profit | 10.7B | 10.4B | 10.8B | 11.4B | 11.6B | 12.6B | 11.9B | 12.2B | 12.5B | 14.6B | 15.3B |
| Operating Income | 3.36B | 2.92B | 3.08B | 3.01B | 3.51B | 2.72B | 4.45B | 3.93B | 4.37B | 6.45B | 5.85B |
| EBITDA | 8.11B | 1.47B | 1.82B | 2.32B | -3.93B | 2.87B | 5.49B | 4.67B | 5.25B | 7.18B | 6.89B |
| Net Income | 5.18B | 67.0M | 34.0M | 900M | -4.54B | 1.11B | 3.56B | 3.00B | 3.30B | 4.76B | 3.66B |
| EPS | 23 | 0.32 | 0.17 | 4.95 | -28 | 7.23 | 25 | 22 | 26 | 38 | 31 |
| Balance Sheet | |||||||||||
| Total Assets | 61.0B | 60.4B | 59.7B | 61.2B | 65.0B | 63.3B | 62.3B | 67.4B | 75.1B | 82.3B | 92.3B |
| Total Liabilities | 48.4B | 48.9B | 50.0B | 54.5B | 63.6B | 65.1B | 63.8B | 69.0B | 76.8B | 83.2B | 95.9B |
| Shareholders' Equity | 12.6B | 11.5B | 9.68B | 6.71B | 1.45B | -1.79B | -1.49B | -1.60B | -1.69B | -2.17B | -3.95B |
| Cash & Short-term Investments | 2.78B | 2.67B | 2.98B | 4.02B | 6.28B | 3.53B | 4.68B | 4.58B | 5.69B | 3.98B | 6.53B |
| Total Debt | 8.55B | 7.88B | 7.60B | 9.40B | 9.41B | 7.54B | 7.30B | 7.39B | 7.39B | 8.61B | 11.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.74B | 4.35B | 4.04B | 4.37B | 4.54B | 4.43B | 5.16B | 4.31B | 6.09B | 6.16B | 5.70B |
| Capital Expenditure | 562M | 580M | 557M | 506M | 641M | 535M | 558M | 687M | 859M | 745M | 470M |
| Free Cash Flow | 4.18B | 3.77B | 3.48B | 3.87B | 3.90B | 3.90B | 4.60B | 3.63B | 5.23B | 5.41B | 5.23B |
| Ratios | |||||||||||
| ROE | 41.1% | 0.6% | 0.4% | 13.4% | -313.9% | - | - | - | - | - | - |
| ROA | 8.5% | 0.1% | 0.1% | 1.5% | -7.0% | 1.8% | 5.7% | 4.5% | 4.4% | 5.8% | 4.0% |
| Net Profit Margin | 2.6% | 0.0% | 0.0% | 0.4% | -1.9% | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% | 0.8% |
| Debt to Equity | 0.68x | 0.68x | 0.78x | 1.40x | 6.50x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
McKesson Corporation dividends
- Dividend yield
- 0.30%
- Forward dividend
- 3.76 USD
- Payout ratio
- 8.0%
- Ex-dividend date
- Dec 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 381M | 3.07 | 8.0% |
| 2025 | USD 345M | 2.69 | 10.5% |
| 2024 | USD 314M | 2.34 | 10.5% |
| 2023 | USD 292M | 2.05 | 8.2% |
| 2022 | USD 277M | 1.80 | 24.9% |
| 2021 | USD 276M | 1.72 | - |
| 2020 | USD 294M | 1.62 | 32.7% |
| 2019 | USD 292M | 1.48 | 858.8% |
| 2018 | USD 262M | 1.25 | 391.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jan 5, 1998.
Who owns McKesson Corporation
- Insiders 0.36%
- Institutions 90.82%
- Public & others 8.81%
- Shares outstanding 115M
- Free float 115M
Top funds holding MCK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.70M | 3.20% | -3.13% | Sep 2026 |
| Vanguard 500 Index Investor | 3.06M | 2.65% | -4.11% | Sep 2026 |
| iShares Core S&P 500 ETF | 1.55M | 1.35% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.52M | 1.31% | -2.89% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 1.42M | 1.23% | -0.25% | Oct 2026 |
| Putnam Large Cap Value A | 1.14M | 0.99% | 0.00% | Sep 2026 |
| Vanguard MStar Value Index Investor | 1.11M | 0.96% | -3.38% | Sep 2026 |
| MFS Value A | 883K | 0.76% | -2.89% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 853K | 0.74% | +0.88% | Oct 2026 |
| Vanguard Dividend Appreciation ETF | 660K | 0.57% | -3.06% | Sep 2026 |
| Vanguard Institutional Index I | 617K | 0.53% | -4.03% | Sep 2026 |
| Fidelity Magellan | 586K | 0.51% | -0.66% | Sep 2026 |
| AllianceBernstein US L/C Growth Eqty MF | 525K | 0.45% | -0.98% | Jun 2026 |
| UniGlobal Vorsorge | 472K | 0.41% | 0.00% | Sep 2026 |
| iShares Russell 1000 Growth ETF | 414K | 0.36% | +0.09% | Oct 2026 |
| Vanguard Health Care ETF | 358K | 0.31% | +0.13% | Sep 2026 |
| iShares MSCI USA Min Vol Factor ETF | 356K | 0.31% | +0.26% | Oct 2026 |
| Swedbank Robur Globalfond A | 326K | 0.28% | 0.00% | Oct 2026 |
| State Street® SPDR® Port S&P 500® ETF | 324K | 0.28% | -0.07% | Oct 2026 |
| JHancock Disciplined Value I | 314K | 0.27% | 0.00% | Sep 2026 |
Top institutions holding MCK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.8M | 9.35% | -5.46% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.85M | 6.80% | -1.35% | Jun 2026 |
| State Street Corp | 5.73M | 4.96% | -0.08% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 5.31M | 4.60% | +130.74% | Jun 2026 |
| Franklin Templeton Inc | 2.91M | 2.52% | -5.16% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.87M | 2.49% | -0.34% | Jun 2026 |
| Geode Capital Management, LLC | 2.82M | 2.44% | -2.81% | Jun 2026 |
| Massachusetts Financial Services Company | 2.45M | 2.12% | -15.65% | Jun 2026 |
| FMR Inc | 2.13M | 1.85% | -40.88% | Jun 2026 |
| JPMorgan Chase & Co | 1.75M | 1.51% | -46.49% | Jun 2026 |
| AllianceBernstein L.P. | 1.69M | 1.46% | -24.71% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.55M | 1.34% | +18.27% | Jun 2026 |
| DZ BANK AG Deutsche Zentral-Genossenschaftsbank Frankfurt am Main | 1.54M | 1.33% | +46.97% | Jun 2026 |
| NORGES BANK | 1.53M | 1.32% | -24.04% | Jun 2026 |
| Northern Trust Corp | 1.44M | 1.25% | -1.36% | Jun 2026 |
| Bank of America Corp | 1.32M | 1.15% | -14.09% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.32M | 1.14% | +1.23% | Jun 2026 |
| Royal Bank of Canada | 1.28M | 1.11% | +0.08% | Jun 2026 |
| Boston Partners Global Investors, Inc | 1.17M | 1.01% | +1.27% | Jun 2026 |
| Nordea Investment Mgmt Bank Demark A/s | 1.03M | 0.89% | +2.64% | Sep 2026 |
McKesson Corporation company profile
- Company name
- McKesson Corporation
- Ticker
- MCK.US
- Exchange
- USA Stocks
- Listed since
- Nov 15, 1994
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 41,600
- Fiscal year end
- March
- Address
- 6555 State Highway 161, Irving, TX, United States, 75039
- Phone
- 972 446 4800
- Website
- mckesson.com
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
McKesson Corporation management
10- Mr. Brian S. Tyler Ph.D.CEO & Chairman · born 1967
- Ms. Michele Lau J.D.Executive VP & Chief Legal Officer · born 1976
- Ms. LeAnn B. SmithExecutive VP & Chief Human Resources Officer · born 1975
- Mr. Kenny K. CheungExecutive VP & CFO · born 1982
- Mr. Napoleon B. Rutledge Jr.Senior VP, Controller & Chief Accounting Officer · born 1973
- Paula AdkisonSenior Vice President of Corporate Finance, Investor Relations & Strategic Finance
- Mr. Francisco J. FragaExecutive VP, Chief Information Officer & CTO · born 1973
- Ms. Jeni DominguezHead of Investor Relations
- Mr. Kirk KaminskyExecutive VP & Group President of North American Pharmaceutical Services
- Mr. Stanton J. McCombPresident of Medical-Surgical